Clinical-stage company INBRAIN Neuroelectronics has reported outcomes from the Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disorders (MINIGRAPH) project.
The MINIGRAPH project is funded by the European Innovation Council. The initiative focused on Parkinson’s disease as its first therapeutic target.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It combined thin-film cortical and subcortical graphene probes with implantable microelectronics, autonomous software, and a minimally invasive surgical delivery system.
The platform aims to improve deep brain stimulation by recording neural activity, interpreting signals, and delivering responsive neuromodulation.
Nanoflex Robotics and ETH Zurich created the interventional system, which uses remote magnetic navigation and an adapted magnetic carrier.
The platform directs implants along straight and curved paths under X-ray guidance. Researchers confirmed the surgical approach through in vitro tests and in vivo evaluations in a large animal model.
INBRAIN co-founder and chief scientific officer Jose Garrido said: “As BCI technologies move toward patients, making them available to more people will depend not only on our ability to manufacture advanced devices, but also on developing precise and reproducible ways to implant them.
“MINIGRAPH brought together the neural interface, intelligent electronics, autonomous software and robotics as a single integrated system. This work helps build the foundation for autonomous neurotherapeutics that can decode neural activity and deliver precise neuromodulation that can be accessible to more patients at scale.”
During the project, the consortium validated an integrated implantable prototype in a translational model.
Accelerated ageing assessments showed projected electrode stability exceeding 10 years, alongside cellular and molecular studies that examined biocompatibility and toxicity.
The accompanying hardware decodes signals across hundreds of neural sites to enable automated stimulation.
ICN2 – Catalan Institute of Nanoscience and Nanotechnology coordinated the consortium.
Alongside INBRAIN Neuroelectronics, ETH Zurich, and Nanoflex Robotics, the participating organisations included Fraunhofer-Gesellschaft, imec, Leiden University Medical Center, and Palacký University Olomouc.
INBRAIN Neuroelectronics is also working with Robeauté to examine microrobotic methods for neural device placement.
